Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

16.050
-0.450-2.73%
Volume:832.00K
Turnover:13.43M
Market Cap:42.68B
PE:10.84
High:16.480
Open:16.480
Low:16.030
Close:16.500
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:1.98
T/O Rate:0.15%
Dividend:0.45
Dividend Rate:2.83%
EPS(LYR):1.480
ROE:6.95%
ROA:1.40%
PB:0.75
PE(LYR):10.84
PS:0.86

Loading ...

Fosun Pharma Subsidiary Secures NMPA Approval for Dobutamine Hydrochloride Injection

Bulletin Express
·
Aug 07

Fosun Pharma Secures NMPA Green Light for Levosalbutamol Nebuliser Solution

Bulletin Express
·
Aug 07

Fosun Pharma Launches Head-to-Head Phase 3 Clinical Trial for a First-in-Class Drug

Deep News
·
Aug 07

Fosun Pharma's Dobutamine Hydrochloride Injection Receives NMPA Marketing Approval

Stock News
·
Aug 07

Shanghai Fosun Pharma - Drug Registration Application for Dobutamine Hydrochloride Injection Approved by Nmpa

THOMSON REUTERS
·
Aug 07

Sinopharm Group Stock Sheds 0.8% in Hong Kong

Dow Jones
·
Aug 07

FOSUN PHARMA Keeps Share Capital Unchanged in July 2026 Monthly Return

Bulletin Express
·
Aug 06

Fosun Pharma Units Get Registration Nod for Two Drugs in China

MT Newswires Live
·
Aug 03

Fosun Pharma Wins NMPA Nod for Empagliflozin–Metformin SR Tablets, Targeting China’s USD 674 Million Diabetes Market

Bulletin Express
·
Aug 03

Fosun Pharma Subsidiary Secures NMPA Green Light for Pediatric Constipation Treatment

Bulletin Express
·
Aug 03

Shanghai Fosun Pharma - Drug Registration Application for Empagliflozin & Metformin Hydrochloride Sustained-Release Tablets(Iii)Approved by Nmpa

THOMSON REUTERS
·
Aug 03

Shanghai Fosun Pharma - Registration Application for Polyethylene Glycol (3350) and Electrolytes Powder Approved by Nmpa

THOMSON REUTERS
·
Aug 03

Shanghai Fosun Pharmaceutical Secures Regulatory Approval for Diabetes Combination Drug

Stock News
·
Aug 03

Sinopharm Group Stock Falls 1.5% in Hong Kong

Dow Jones
·
Jul 31

Fosun Pharma's investment fund successfully completes registration with securities authorities

Stock News
·
Jul 29

Sinopharm Group Stock Climbs 2.6% in Hong Kong

Dow Jones
·
Jul 29

Sinopharm Group Stock Climbs 2.0% in Hong Kong

Dow Jones
·
Jul 27

Fosun Pharma Gains Approval for Clinical Trial of Parkinson's Disease Treatment DM1001

Deep News
·
Jul 26

Fosun Pharma Unit Gets China Clinical Trial Approval for Parkinson's Drug

MT Newswires Live
·
Jul 24

Shanghai Fosun Pharma - Approval from National Medical Products Administration for Clinical Trial of Dm1001 Formulation

THOMSON REUTERS
·
Jul 24